3-CMC

# Research Output: 3-CMC (3-Chloromethcathinone / Clophedrone)

**Substance:** 3-CMC | **PSX ID:** PSX-0415 | **Slug:** 3-cmc
**Research Date:** 2026-05-08 | **Provenance ID:** 64342c5a-7594-4b03-9d13-05f62865005a

---

## Chemical Identity

**Verified from PubChem CID 50999285 [Ref 29 database lookup]:**

| Property | Value |
|---|---|
| IUPAC name | 1-(3-chlorophenyl)-2-(methylamino)propan-1-one |
| Molecular formula | C₁₀H₁₂ClNO |
| Molecular weight | 197.66 g/mol |
| InChIKey | VOEFELLSAAJCHJ-UHFFFAOYSA-N |
| PubChem CID | 50999285 |
| CAS (freebase) | 1049677-59-9 |
| CAS (HCl salt) | 1607439-32-6 |
| SMILES (derived) | CNC(C)C(=O)c1cccc(Cl)c1 |

**FLAG (safety-critical):** The SMILES string above is derived from the IUPAC name rather than read directly from a database record (PubChem's JavaScript-dependent page could not be parsed). Generation agent should verify against PubChem CID 50999285 or Cayman Chem product 44462 before publishing.

**Structural notes:** 3-CMC is a β-keto analog of amphetamine with an N-methyl group and a chlorine substituent at the meta (3-) position of the phenyl ring. It possesses a chiral centre at C2 of the propan-1-one backbone, producing two enantiomers: (R)- and (S)-3-CMC. The compound is sold on the illicit market as a racemate (Langa et al. 2026 [Ref 3]).

**Discrepancies with brief:** The brief contains no SMILES, formula, weight, or InChIKey. All above data are newly verified additions. PubChem CID (50999285) was confirmed via API lookup.

**Alternative names:** Clophedrone (the brief lists this as a street-name candidate; it is more accurately a semi-systematic alternative designation appearing in some published literature (Trynda et al. 2026) alongside the common abbreviation 3-CMC).

---

## Pharmacology

### Mechanism of Action

3-CMC functions as a non-selective monoamine releasing agent (substrate-type releaser) at the dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin transporter (SERT). This places it in the same pharmacological category as mephedrone and other ring-substituted methcathinone analogs.

**Direct evidence (animal/in vitro):**
- Wojcieszak et al. (2020 [Ref 6]) demonstrated that chloromethcathinones (including 3-CMC and 4-CMC) "enhance non-selective DA/5-HT release," consistent with substrate-type releaser activity at DAT and SERT. This contrasts with α-pyrrolidinophenone cathinones, which act as reuptake inhibitors.
- The same study confirmed dose-dependent horizontal locomotor stimulation in mice, a behavioral signature of monoamine release.

**Structural analog inference:**
- 4-CMC (4-chloromethcathinone), the positional isomer with the chlorine at the para position rather than meta, has been directly characterized at monoamine transporters in rats by Chojnacki et al. (2023 [Ref 7]). 4-CMC functions as a substrate at DAT, NET, and SERT with comparable potency across all three transporters, similar to mephedrone. In the same study, 4-CMC increased blood pressure, heart rate, and locomotor activity in rats. By structural analogy, 3-CMC is expected to exhibit similar transporter pharmacology, though the meta-chloro substitution may alter relative DAT/SERT potency.
- Cozzi et al. (2013 [Ref 9]) demonstrated that meta-ring substitution on methcathinone analogs (trifluoromethyl series) increases SERT potency relative to DAT compared to unsubstituted analogs, suggesting 3-CMC may have relatively more serotonergic activity than mephedrone.
- Baumann et al. (2018 [Ref 25]) established the canonical framework: ring-substituted cathinones are transporter substrates (releasers), not blockers. All cathinones increase extracellular monoamine concentrations in the brain.

**FLAG:** No published study has measured specific Ki or EC50 values for 3-CMC at DAT, SERT, or NET in standardized radioligand binding or release assays. The characterization as a "non-selective monoamine releasing agent" is derived from (a) the Wojcieszak 2020 behavioral data, (b) in vitro characterization of the structural analog 4-CMC, and (c) class-level SAR principles. This gap should be noted prominently in the article.

### Pharmacokinetics

**Human data (direct, 3-CMC):**
Di Trana et al. (2026 [Ref 1]) conducted the first in-human study of 3-CMC metabolism. In an observational naturalistic design (n=16 regular psychostimulant users), participants self-administered:
- **Oral:** 100–150 mg
- **Intranasal:** 60–80 mg

Urine was collected in two intervals (0–2 h and 2–5 h). Nine metabolites were identified: 4 phase I and 5 phase II. Key findings:
- Parent drug detected in all samples at different levels
- **Route-dependent metabolism:** Three metabolites (including two N-acetylated forms and one carboxylated metabolite) were exclusive to oral administration, suggesting N-acetylation occurs primarily via first-pass/gut metabolism
- β-OH-3-CMC accumulated more after intranasal administration
- 3-CMC N-glucuronidation was hypothesized for the first time in this study

**Metabolism (hepatic):**
Berardinelli et al. (2024 [Ref 5]) conducted the most comprehensive human metabolite profiling, identifying 12 metabolites for 3-CMC via human hepatocyte incubation with LC-HRMS/MS confirmation in clinical/forensic casework (blood, urine, oral fluid). Major metabolic reactions:
- **Ketoreduction** (of β-keto group → dihydro-3-CMC)
- **N-demethylation**
- **Combined N-demethylation + ω-carboxylation** → this combination produced the predominant urinary metabolite — a previously unreported pathway for any methcathinone analog

Feliu et al. (2025 [Ref 12]) confirmed four primary HLM metabolites: M1 (hydroxylation of aliphatic group), M2 (N-demethylation), M3 (β-keto reduction / dihydro-3-CMC), M4 (M1 + β-keto reduction). M3 was predominant in postmortem samples.

Mestria et al. (2025 [Ref 13]) confirmed, in a murine DBS model, that dihydro-CMC stereoisomers and N-demethyl-CMC are key metabolites. Stability data from DBS: 3-CMC decreased 67–82% over 30–90 days; N-demethyl-3-CMC decreased 48–88%; dihydrometabolites only −5% to −37%, remaining detectable to 90 days.

**CYP enzyme involvement:**
No direct CYP data exist for 3-CMC. By structural analogy to mephedrone: Olesti et al. (2019 [Ref 14]) demonstrated that mephedrone (4-methylmethcathinone) metabolism is mediated by CYP2D6 in a Phase I clinical trial. Individuals with low or absent CYP2D6 activity were at higher risk of toxicity. It is reasonable to anticipate similar CYP2D6 involvement for 3-CMC, though this has not been directly tested. **FLAG for structural-analogy inference.**

**Enantiomers:**
Langa et al. (2026 [Ref 3]) demonstrated enantioselective metabolism in Wistar rats following acute i.p. exposure (10 or 20 mg/kg). Both 3-CMC and its three pairs of enantiomeric metabolites showed enantiomeric fractions (EF) different from 0.5, confirming enantioselective metabolic processes. Clinical implications of enantioselectivity (differential activity of R vs S enantiomers at transporters) have not been characterized for 3-CMC specifically.

**Instability in biological matrices:**
Romańczuk et al. (2023 [Ref 11]) documented complete 3-CMC decomposition in blood at 4°C within approximately 2 months. Dihydro-CMC (reduced metabolite) showed superior stability and was detectable even when parent drug was absent. Only 44% of 27 forensic cases showed detectable parent compound. This has major implications for forensic and clinical detection: immunoassays will produce false-negative results, and metabolite-inclusive screening is required.

---

## History

**Discovery and first synthesis:**
3-CMC was not developed for clinical use and has no known therapeutic history. It appears to have been synthesized as a recreational designer drug analogous to methcathinone and mephedrone. No publication records a specific synthesis date or originating laboratory.

**Market emergence:**
3-CMC was first identified on the European drug market in **September 2014** based on a police confiscation in Sweden (EMCDDA initial report [Ref 19]; Wikipedia [web-retrieved]). It was tracked by the EMCDDA through the EU Early Warning System from 2014 onward.

**Market context:**
3-CMC emerged as a successive market replacement in the synthetic cathinone substitution sequence: mephedrone (4-MMC) controlled internationally in 2010 → 4-CMC emerged → 4-CMC placed under international control in 2020 → 3-CMC emerged as dominant substitute. The EUDA drug market report [Ref 17] documents that the supply source shifted from China (which introduced domestic legal controls post-2015) to India, which became the dominant export country by 2019–2020. By 2022, approximately 94% of cathinones seized in Europe originated from India, with the Netherlands intercepting 83% of that quantity.

**Scale of prevalence:**
- 2020: 880 kg of 3-CMC seized in Europe
- 2022: **19,414 kg** seized across Europe in 2,997 individual seizure cases — the largest single NPS seizure quantity recorded at that time [Ref 17]
- 2023: 3-CMC accounted for >46% of all NPS-related seizures (Langa et al. 2026 [Ref 3])
- 2024: 3-CMC accounted for **over 63%** of all NPS seized in Europe (Di Trana et al. 2026 [Ref 1])
- Detected in **25 European countries** by 2021 (EMCDDA data)
- Wholesale price in Netherlands 2022: approximately EUR 2,025 per kilogram [Ref 17]
- Domestic production documented in Netherlands and Poland (from dismantled lab investigations) [Ref 17]

**Regulatory history:**
- November 2021: Extended EMCDDA Scientific Committee conducted formal risk assessment; 10 confirmed deaths with 3-CMC reported via EU EWS at that time [Ref 18]
- **March 18, 2022:** European Commission adopted delegated act adding 3-CMC to the definition of "drug" under EU law, amending the Annex to Council Framework Decision 2004/757/JHA [Ref 18]
- **October 2023:** WHO Expert Committee on Drug Dependence (46th ECDD) recommended 3-CMC for placement in **Schedule II of the 1971 Convention on Psychotropic Substances** [Refs 20, 29]
- **March 4, 2024:** EU Council Decision 2024/832 formally endorsed the Schedule II placement [Ref 21]
- **March 2024:** First confirmed detection in the United States (oral fluid specimens, New York City, by the Center for Forensic Science Research & Education) [Ref 23]

---

## Subjective Effects

**Note on evidence quality:** No randomized controlled human study of 3-CMC has been published. Available human data derive from: (a) an observational naturalistic study focused on metabolism (Di Trana et al. 2026 [Ref 1]); (b) the Italian Poison Control Centre case series (Bassi et al. 2025 [Ref 2]); and (c) postmortem and forensic toxicology cases. Subjective effect descriptions are supplemented by user-report data (PsychonautWiki [Ref 22]) and structural analog data (mephedrone clinical studies [Refs 15, 16]).

**From human intoxication cases (Italy, 2014–2025):**
Bassi et al. (2025 [Ref 2]) reported a series of 3-CMC-related intoxications registered at the PCC-National Toxicology Information Centre. All documented intoxications were non-fatal. All involved male patients. Documented effects:
- **Stimulant/sympathomimetic:** Psychomotor agitation, aggressiveness, tachypnea
- **Psychiatric:** Psychosis
- **CNS depression** (at higher doses/polydrug contexts)
- **Cardiovascular:** Cardiac arrhythmias, thoracic pain
- **Autonomic:** Tachypnea

**From animal studies (mice, Bassi et al. 2025 [Ref 2]):**
3-CMC (0.1–30 mg/kg i.p., CD-1 mice) produced:
- Dose-dependent **locomotor stimulation** (horizontal activity)
- **Tachypnoea**
- **Hypothermia** (rather than hyperthermia, in contrast to some other cathinones — notable finding)
- Sensorimotor alterations and **prepulse inhibition (PPI) disruption** only at high doses (1 and 10 mg/kg tested for PPI)
- Minor sex differences observed

**From animal studies (mice, Wojcieszak et al. 2020 [Ref 6]):**
3-CMC produced dose-dependent horizontal locomotor stimulation; did not elevate vertical locomotor activity (rearing), distinguishing it from α-pyrrolidinophenone-class cathinones (which are DAT blockers). This behavioral distinction reflects the releaser vs. blocker mechanism.

**User-report data (PsychonautWiki [Ref 22]; label as user reports):**
Described as producing stimulant and entactogenic effects similar to mephedrone, including euphoria, sociability enhancement, stimulation, and tactile effects. Psychonautwiki notes effects described as "similar to mephedrone and, to a lesser extent, those of MDMA and cocaine." These are community reports and have not been validated in controlled studies.

**Effects taxonomy mapping (proposed, pending editorial review):**
Based on the stimulant/entactogen class profile and documented human intoxication data:
- *Body:* stimulation, wakefulness, appetite-suppression, bruxism, excessive-sweating, heart-rate-perception-changes, vasoconstriction, abnormal-heartbeat, dry-mouth, pupil-dilation
- *Feeling:* euphoria, anxiety, paranoia
- *Thinking:* thought-acceleration, focus-enhancement (at low doses), compulsive-redosing-urge
- *Self:* sociability-enhancement, disinhibition, empathy-enhancement
- **FLAG:** These mappings are inferred from class effects and human intoxication descriptions; no controlled study has systematically assessed subjective effects using validated scales.

**Duration:**
- No published pharmacokinetic Tmax or plasma half-life data from human studies.
- PsychonautWiki [Ref 22] reports user-consensus duration data (label as community consensus):
  - *Oral:* Total 3–5 hours
  - *Intranasal:* Total 2–4 hours
- Di Trana et al. (2026 [Ref 1]) collected urine at 0–2 h and 2–5 h post-dose, confirming metabolites are detectable within 2 hours and persist through 5 hours, consistent with active drug exposure in that window.
- **FLAG:** No published controlled study provides validated onset, peak, and offset data for 3-CMC in humans.

---

## Safety & Toxicity

### Deaths and Severe Adverse Events

**Fatal cases:**
- At the time of the November 2021 EU risk assessment, **10 confirmed deaths** with 3-CMC exposure had been reported through the EU Early Warning System [Ref 18]
- Romańczuk et al. (2023 [Ref 11]) reported 27 deaths at one Polish forensic medicine department (2016–2022) involving CMC isomers. 13/27 cases involved 3-CMC. Of all 27 cases, 8 deaths were attributed primarily to CMC toxicity; in 74% (20 cases) xenobiotic poisoning was the determined cause of death. The remaining 7 deaths involved non-toxicological mechanisms (stabbing, drowning, traffic accidents, fire) with CMC as an incidental finding.
- Pélissier-Alicot et al. (2026 [Ref 24]) reported a fatal **chemsex** case: a 62-year-old man found dead with chemsex paraphernalia. Cause: toxic GHB concentration (330 µg/mL) in combination with 3-CMC (17 ng/mL in frozen blood). This represents a documented 3-CMC-associated fatality in a polydrug chemsex context.
- ECDD data (2023 [Ref 29]): Fatal intoxications documented in which 3-CMC was the **sole identified substance**.

**Note on polydrug context:** Romańczuk et al. [Ref 11] found that 82% of CMC cases (22/27) involved co-detected substances, including synthetic cannabinoids, synthetic opioids, cocaine, opiates, medications, and/or ethanol. Isolating the contribution of 3-CMC alone to fatality is methodologically challenging.

### Blood Concentrations

From Romańczuk et al. (2023 [Ref 11]):
- Non-fatal intoxication range: Based on the forensic literature and analogous 4-CMC data (Tomczak et al. 2018 [Ref 7 context]): non-fatal 4-CMC blood concentrations ranged 1.3–75.3 ng/mL; 4-CMC fatality concentrations 56.2–1870 ng/mL
- 3-CMC blood concentrations in the forensic series: **10–2,800 ng/mL** [Ref 11]
- **FLAG:** No established therapeutic index or documented lethal blood concentration specific to 3-CMC. The 2,800 ng/mL concentration was in a postmortem sample tested 42 days post-autopsy, with documented post-mortem redistribution and degradation effects.

### Organ Toxicity

Langa et al. (2026 [Ref 3]) administered 3-CMC (10 or 20 mg/kg i.p.) to Wistar rats and sacrificed at 24 h. Key findings:
- **Biochemical:** Decreased plasma CK-MB, alkaline phosphatase, AST; increased glucose and urea; decreased urinary albumin
- **Oxidative stress and energy biomarker alterations:** brain, lungs, kidneys
- **Histopathological changes:** brain, liver, lungs (both doses); kidneys (high dose only)
- **Species note:** Rat i.p. study; relevance to human oral/intranasal use requires extrapolation caution.

### Cytotoxicity

Wojcieszak et al. (2020 [Ref 6]) provided the first in vitro cytotoxicity data for 3-CMC on SH-SY5Y human neuroblastoma cells. Cytotoxicity emerged and intensified with prolonged incubation, suggesting an **indirect mechanism** not directly related to monoamine transporter interactions (unlike acute neurotoxicity from monoamine depletion).

### Cardiovascular Risk

- Human intoxication cases: cardiac arrhythmias and thoracic pain documented [Ref 2]
- ADMET predictions: cardiotoxicity risk predicted for 3-CMC and all CMC compounds (Bassi et al. 2025 [Ref 2])
- 4-CMC analog: increased blood pressure and heart rate in rats (Chojnacki et al. 2023 [Ref 7])
- Drug-drug interaction potential predicted via ADMET analysis [Ref 2]
- **FLAG:** No hERG binding data or QTc prolongation data found for 3-CMC in published literature.

### Neurotoxicity

The systematic review by Daziani et al. (2023 [Ref 30]) documents class-level neurotoxic effects of synthetic cathinones including: encephalopathy, coma, convulsions, sympathomimetic and hallucinogenic toxidromes, excited/agitated delirium syndrome, and serotonin syndrome risk. These have not been characterized in 3-CMC-specific controlled studies.

---

## Harm Reduction

**Detection and testing:**
- Standard immunoassay toxicology screens (EMIT-type) cross-react with 3-CMC: Willeman et al. (2025 [Ref 4]) demonstrated 3-CMC caused false-positive MDMA results at 100 µg/mL and contributed to 17.1% of false-positive MDMA tests in a clinical cohort. Confirmatory LC-MS/MS or GC-MS is required for definitive identification.
- Dihydro-3-CMC metabolite is a reliable intake biomarker even when parent drug has degraded [Ref 11, Ref 13]
- Forensic samples should be frozen at −20°C immediately after collection to preserve cathinone content [Ref 24]

**Adulteration risk:**
- 3-CMC has been increasingly sold as MDMA or used to adulterate MDMA in European markets [Ref 17]. Drug checking (reagent testing, FTIR, GC-MS) is essential; Marquis/Mecke reagents will not reliably identify 3-CMC.

**Administration routes and harm:**
- Intranasal use (snorting) is common; oral and injection also documented [Ref 29]
- "Chemsex" (slamming/injecting in sexual contexts) is documented with 3-CMC [Ref 18, Ref 24]
- The fatal chemsex case [Ref 24] highlights particular danger in combination with GHB, which is also prevalent in chemsex settings
- Psychonautwiki specifically discourages insufflation [Ref 22] — user community harm reduction

**Clinical management:**
Based on synthetic cathinone class principles (no 3-CMC-specific protocols published):
- Benzodiazepines for agitation, psychomotor excitation, and seizure threshold reduction
- Active cooling for hyperthermia (though 3-CMC animal data show hypothermia rather than hyperthermia in mice — this finding warrants caution in applying generic cathinone hyperthermia protocols)
- Cardiac monitoring for arrhythmias
- Renal function monitoring given nephrotoxicity signal in rat data [Ref 3]
- Serotonin syndrome monitoring if co-administered with serotonergic agents

---

## Tolerance & Dependence

**Direct 3-CMC data:** No controlled studies on tolerance development, cross-tolerance, or withdrawal characterize 3-CMC specifically.

**ECDD assessment (2023 [Ref 29]):** Dependence is expected to be similar to that produced by amphetamine and other psychostimulants. Clinical admissions associated with 3-CMC dependence have been reported.

**Structural analog inference (3-MMC, van Amsterdam et al. 2025 [Ref 28]):**
3-MMC, the meta-methyl analog (structurally analogous to 3-CMC with methyl rather than chloro at the meta position), shows a pattern directly relevant to 3-CMC dependence risk assessment:
- Shorter duration of action relative to mephedrone (4-MMC) leads to **increased craving and more frequent redosing**
- In the Netherlands, treatment-seeking for problematic 3-MMC use increased from 33 cases (2021) to 330 cases (2023) following legal ban
- Most cases involved polydrug users
The compulsive redosing pattern reported with 3-MMC and documented by users of 3-CMC via community reports (PsychonautWiki [Ref 22]) is consistent with high dependence liability.

**FLAG:** All tolerance/dependence data for 3-CMC itself are inferred from class or structural analog data. No published withdrawal characterization exists for 3-CMC. The generation agent should note this gap explicitly.

---

## Interactions

**Documented interactions:**

**GHB (gamma-hydroxybutyrate):**
Pélissier-Alicot et al. (2026 [Ref 24]) documented a **fatal case** involving 3-CMC + GHB in a chemsex context (GHB 330 µg/mL toxic, 3-CMC 17 ng/mL). The combination of a stimulant cathinone with CNS depressants including GHB carries high risk from cardiovascular stress plus respiratory depression.

**Alcohol:**
Papaseit et al. (2019 [Ref 16]) demonstrated in a randomized crossover trial that mephedrone combined with alcohol (0.8 g/kg) produced significantly increased cardiovascular effects and greater euphoria than either drug alone, with mephedrone reducing alcohol's sedation. By structural analogy, 3-CMC + alcohol is expected to potentiate cardiovascular toxicity and subjective effects, increasing abuse liability. **FLAG: structural analog inference.**

**MAOIs (monoamine oxidase inhibitors):**
No published study characterizes 3-CMC + MAOI interactions directly. Class-level contraindication: monoamine releasers combined with MAOIs carry high risk of hypertensive crisis and serotonin syndrome. This interaction should be flagged as safety-critical regardless of the absence of 3-CMC-specific data. **FLAG: class inference, safety-critical.**

**CYP2D6 inhibitors:**
If CYP2D6 is the primary metabolizing enzyme for 3-CMC (as established for mephedrone [Ref 14]), co-administration with CYP2D6 inhibitors (e.g., fluoxetine, paroxetine, bupropion) could increase 3-CMC plasma exposure and toxicity risk. **FLAG: structural analog inference, safety-critical.**

**Synthetic cannabinoids, synthetic opioids:**
Romańczuk et al. (2023 [Ref 11]) documented frequent co-detection of CMC isomers with synthetic cannabinoids and synthetic opioids in fatal forensic cases. These are empirically high-risk polydrug combinations.

**Serotonin syndrome risk:**
As a serotonin releaser (by class mechanism), 3-CMC combined with SSRIs, SNRIs, triptans, or other serotonergic agents raises serotonin syndrome risk. No published case reports document 3-CMC-specific serotonin syndrome. Daziani et al. (2023 [Ref 30]) documents serotonin syndrome in the broader synthetic cathinone class.

---

## Legal Status

### European Union
- **Controlled since March 18, 2022** via EU delegated act amending Council Framework Decision 2004/757/JHA — adds 3-CMC to definition of "drug" under EU law [Ref 18]
- **Schedule II of the 1971 Convention on Psychotropic Substances** — supported by EU Council Decision 2024/832 of March 4, 2024 [Ref 21], following WHO ECDD 46th meeting recommendation [Ref 20]

### United Kingdom
- Covered by the **Psychoactive Substances Act 2016** (blanket psychoactive substance prohibition, effective May 26, 2016), which prohibits production, supply, and import/export of all psychoactive substances not otherwise exempted. 3-CMC is not listed as an exempted substance.
- Not specifically named as a Class A/B/C drug under the Misuse of Drugs Act 1971 based on available evidence — but PSA 2016 provides operative control.

### United States
- **Not explicitly scheduled** under the Controlled Substances Act (CSA) at time of research (May 2026).
- The DEA/FDA published a Request for Comments in the Federal Register (August 2023 and February 2024) regarding international scheduling recommendations for 3-CMC in advance of WHO and UN CND consideration [web-retrieved, Federal Register 2023-16812 and 2024-02573].
- 3-CMC may be subject to the **Federal Analogue Act** (FAA) if it is substantially similar in structure or pharmacology to a Schedule I/II controlled substance and intended for human consumption — but analogue enforcement for cathinones has been inconsistent and no specific scheduling action for 3-CMC was confirmed in the literature.
- First US detection: March 2024, New York City (CFSRE [Ref 23])
- **FLAG:** US scheduling status requires verification against current DEA scheduling actions post-2024.

### Australia
- No specific scheduling data found in the literature reviewed.
- **FLAG:** Australian scheduling status (ARTG, SUSMP) was not verified. Generation agent should consult TGA scheduling database.

### Canada
- No specific scheduling data found in the literature reviewed.
- **FLAG:** Canadian CDSA scheduling status was not verified. Generation agent should consult Health Canada CDSA schedules.

### International
- **WHO ECDD 46th Meeting (October 16–20, 2023):** Recommended 3-CMC for **Schedule II of the Convention on Psychotropic Substances of 1971** [Refs 20, 29]
- **UN Commission on Narcotic Drugs:** Expected to act on WHO recommendation; EU endorsed via 2024/832

---

## Clinical Trials

No registered clinical trials were found for 3-CMC on ClinicalTrials.gov. No Phase I, II, or III trials exist. The compound has no approved therapeutic application.

The Di Trana et al. (2026 [Ref 1]) study — while providing the most direct human pharmacological data — is described as "observational, uncontrolled, naturalistic" and does not constitute a clinical trial.

---

## Community Feedback Analysis

**No community feedback submitted.** The brief's Part A2 was empty. This section is left blank accordingly.

---

## Gaps & Flags

### Critical Data Gaps

1. **⚠️ FLAG — No DAT/SERT/NET Ki or EC50 values for 3-CMC:** The mechanism is inferred from behavioral studies, structural analog data (4-CMC), and class-level SAR. No published study has measured 3-CMC directly in standardized radioligand binding or neurotransmitter release assays.

2. **⚠️ FLAG — No published human pharmacokinetics (Tmax, plasma half-life, AUC, bioavailability by route):** The Di Trana 2026 study describes metabolic profiling but does not report plasma concentration–time curves or PK parameters.

3. **⚠️ FLAG — No validated dose-duration data from controlled human studies:** PsychonautWiki community data (oral threshold 30 mg, common 60–100 mg, strong 100–180 mg, heavy 180+ mg) are from user reports; the Di Trana 2026 naturalistic study used 100–150 mg oral and 60–80 mg intranasal self-administration. These are the only human dose references available but are not from controlled trials.

4. **⚠️ FLAG — SMILES string is structure-derived, not API-confirmed:** The SMILES CNC(C)C(=O)c1cccc(Cl)c1 is correct by structure but should be verified against PubChem CID 50999285 before publishing.

5. **⚠️ FLAG — No established lethal blood concentration or therapeutic index:** The highest documented blood concentration is 2,800 ng/mL (postmortem, with severe degradation caveats). No controlled LD50 or therapeutic index data exist for humans.

6. **⚠️ FLAG — US and Australian/Canadian legal status unverified:** Federal Register activity suggests US scheduling consideration is pending; confirmed scheduling status should be verified from live databases.

7. **⚠️ FLAG — CYP enzyme involvement is structural-analog inference only:** CYP2D6 is implicated by analogy with mephedrone but has not been characterized for 3-CMC.

8. **⚠️ FLAG — No published withdrawal characterization for 3-CMC:** Dependence and withdrawal data are class-inferred from amphetamine analogs and structural analog (3-MMC) patterns.

9. **⚠️ FLAG — Hypothermia vs. hyperthermia:** Mouse data from Bassi 2025 showed hypothermia with 3-CMC, while most synthetic cathinones produce hyperthermia. This discrepancy may be species- or dose-specific and has clinical implications for treatment protocols. Generation agent should note this uncertainty.

10. **⚠️ FLAG — No characterization of the active enantiomers:** 3-CMC is sold as a racemate, and enantioselective metabolism is confirmed (Langa 2026), but the relative activity of R- vs S-3-CMC at each monoamine transporter has not been published.

### Safety-Critical Values Not Yet Confirmed by Published Sources
- LD50: Unknown
- Therapeutic index: Unknown
- Cardiac dose thresholds for arrhythmia: Not established
- Safe blood concentration thresholds: Not established
- hERG/QT effects: Predicted by ADMET but not measured

---

*Research completed: 2026-05-08. 31 citations in registry. Generation agent should use [Ref N] format and match to 01-citations-registry.json.*